University of California

07/17/2025 | News release | Distributed by Public on 07/17/2025 19:33

A CRISPR approach to neurodegenerative diseases

When Martin Kampmann, Ph.D., set out to explore the workings of the human brain, he was captivated by its greatest mystery: how a network of cells could produce something as intangible as thoughts, emotions, memories, and even consciousness.

Martin Kampmann, Ph.D., delivers the 2025 Byers Lecture.

Sonya Yruel

This lifelong curiosity, paired with a personal motivation to combat dementia, has shaped a research career at the leading edge of neurodegenerative science. Kampmann shared his compelling journey and dedication to discovering new therapies to treat neurodegenerative diseases in their earliest stages at this year's annual Byers Award Lecture in May.

"I was motivated to research neurodegenerative diseases because I had experienced how devastating these diseases are through my grandmother, who suffered from dementia," said Kampmann, the Dorothy Bronson Professor in the Department of Biochemistry and Biophysics and a member of the Institute for Neurodegenerative Diseases. "With a molecular-level understanding of neurodegenerative diseases, my goal is to find new therapies that can intervene and stop these diseases in their tracks."

Discovery beyond boundaries

At the lecture, UCSF Chancellor Sam Hawgood, the Arthur and Toni Rembe Rock Distinguished Professor, introduced Kampmann's work as a bold effort to uncover the cellular mysteries of brain health, understand the biological mechanisms that go awry in disease, and ultimately develop safe, effective therapies that could transform patients' lives.

Chancellor Hawgood also acknowledged Brook Byers, a lifetime member of the UCSF Foundation Board of Directors, his wife, Shawn, and his sons, Blake and Chad, for 30 years of supporting basic science and founding the award, which recognizes science's role in advancing knowledge, driving innovation, and addressing global challenges.

"The Byers' unwavering support for basic science has had a profound and lasting impact on UCSF," Chancellor Hawgood said. "Thanks to their belief in UCSF, the Byers Award has become a cornerstone of our scientific community. It inspires our researchers and fuels bold, world-changing discoveries. For 30 years, this award has celebrated the spirit of innovation and excellence that defines UCSF at its best."

Hosted by the Sandler Program for Breakthrough Biomedical Research (PBBR), the Byers Award supports outstanding research of mid-career faculty members whose innovative ideas often are deemed too high-risk by the National Institutes of Health and other large funding entities.

Like the Byers Award, PBBR supports curiosity-driven science and has achieved remarkable success. It has generated nearly 4,000 peer-reviewed scientific publications and 127 patents, and has supported almost 1,100 investigators. Recipients of PBBR awards have generated discoveries that have resulted in $1.81 billion in funding for scientific research.

From molecules to the mind

Kampmann's spirit of fearless exploration is exactly what the Byers Award was created to support. His path to UCSF began in Germany and in Cambridge in the UK, where he studied human biology and biochemistry before pursuing a doctorate at The Rockefeller University. There, he investigated how molecules move between the nucleus and the surrounding space of the cell, establishing the groundwork for understanding how cells function.

UCSF is one of the few places in the world where innovative strategies are able to succeed because of the robust neuroscience community support.
Martin Kampmann, Ph.D.

His desire to view biology beyond a molecular lens ultimately led him to UCSF for postdoctoral training in the lab of Jonathan Weissman, PhD, who at the time was a professor in the Department of Cellular and Molecular Pharmacology. As a postdoc, Kampmann led the creation of a tool that helps scientists find important human genes involved in specific cell processes and understand how those genes work together in complex networks.

"The timing was great because CRISPR technology was just being developed by [UC Berkeley biochemist and Nobel laureate] Jennifer Doudna," Kampmann said. "We were able to take advantage of these exciting new technologies to build a CRISPR-based genetic-screening platform, which allowed us to systematically study genes across the human genome. The purpose was to identify which genes play important roles in specific cellular processes and better understand their functions."

Kampmann credits UCSF's collaborative environment and bold research culture with helping him make the leap from biochemistry to neuroscience. One especially fruitful collaboration has been with the Memory and Aging Center's Neurodegenerative Disease Brain Bank, led by Lea Grinberg, MD, PhD, the John Douglas French Alzheimer's Foundation Professor, and William Seeley, MD, the Zander Family Distinguished Professor of Neurology.

Together, they used advanced genetic research methods to identify, for the first time, the specific molecules found in the neurons most affected by Alzheimer's disease in the brain region that shows early signs of the condition.

"UCSF is one of the few places in the world where innovative strategies are able to succeed because of the robust neuroscience community support," Kampmann said. "These kinds of partnerships ground our discoveries and make our models stronger."

With 30 years of advancing scientific breakthroughs, the Byers Award in Basic Science remains a catalyst for innovation, supporting exceptional mid-career researchers as they pursue groundbreaking projects.

The power of people and data

Kampmann's research is now focused on how human cells maintain healthy and balanced proteins, a process known as "proteostasis." By studying the network of systems inside cells that protect and manage proteins, Kampmann aims to understand how this network breaks down or changes in diseases like cancer and Alzheimer's.

One finding he found particularly surprising was the identification of a previously unknown protein that signals when mitochondria - the parts of cells that produce energy - are under stress. This discovery has shaped research into how cells respond to damage and what goes wrong in diseases like Alzheimer's. Kampmann's also leveraging artificial intelligence (AI) to uncover the drivers of changes in neural activity during the early stages of neurodegeneration.

"There's untapped potential in finding better ways to computationally integrate data that people have generated in human genetics and uncover patterns that we can then test in the lab," Kampmann said. "We're already using AI to understand what controls changes in neural activity that are seen early on in neurodegenerative diseases."

Looking ahead, Kampmann is optimistic, but realistic, about reaching his ambitious goal: unlocking the mechanisms of neurodegenerative diseases to develop new treatments.

"I'm extremely grateful for the Byers Award because it is unrestricted funding that enables us to do high-risk, high-reward research," Kampmann said. "We can try big, bold, new ideas that we believe could lead to a major breakthrough."

For Brook Byers, the impact of his investment in UCSF has gone far beyond advancing science. It has created lasting personal connections and a sense of shared purpose, as seen in the anniversary video that was featured during the lecture.

"Our family has enjoyed our philanthropic relationship with UCSF over many years. It has opened the opportunity to get to know scientists and clinicians on a personal level," Byers said. "Now more than ever, basic science needs our support to drive discoveries that can improve lives."

2025 Byers Award

The Byers Award recognizes outstanding research by faculty members in the middle of their careers.

Martin Kampman's honorary lecture is titled "A CRISPR approach to neurodegenerative diseases."

Watch the full lecture

University of California published this content on July 17, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 18, 2025 at 01:33 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io